Lerociclib

Lerociclib

Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. Preliminary Phase 1b clinical data presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting have demonstrated proof-of-concept in estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. We are exploring the potential for lerociclib to be dosed with less monitoring for neutropenia than other CDK4/6 inhibitors, which would be a significant point of differentiation.

Lerociclib is currently being evaluated in two Phase 1/2 clinical trials: a trial in combination with Faslodex® for patients with ER+, HER2- breast cancer (NCT02983071) and a trial in combination with Tagrisso® (osimertinib) in EGFRm non-small cell lung cancer (NCT03455829).